Richard M. Goldberg
MD
Professor of Medicine; Deputy Director, Clinical Research
👥Biography 个人简介
Richard M. Goldberg, MD is Professor of Medicine and Deputy Director of Clinical Research at The Ohio State University Comprehensive Cancer Center (The James). A career-long leader in gastrointestinal oncology, he is best known for leading the pivotal N9741 trial, which directly compared FOLFOX4 versus FOLFIRI versus IFL in first-line metastatic colorectal cancer—one of the most influential head-to-head chemotherapy trials in mCRC and a cornerstone of evidence guiding modern chemotherapy selection. The N9741 trial, published in the Journal of Clinical Oncology in 2004, demonstrated superior response rates, progression-free survival, and overall survival for FOLFOX4 compared with IFL in mCRC, establishing FOLFOX as a preferred first-line backbone in the United States and supporting the FDA approval of oxaliplatin for mCRC. This work, combined with his extensive contributions to adjuvant colorectal cancer therapy through NCCTG/Alliance cooperative group leadership, has profoundly shaped global treatment algorithms for colorectal cancer over the past two decades. Dr. Goldberg has been a senior leader in NCI cooperative group research, including service as chair and vice chair of the NCCTG (now Alliance for Clinical Trials in Oncology) GI committee. He has authored more than 300 peer-reviewed publications and has mentored numerous fellows and junior faculty who have gone on to leadership positions in academic oncology.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
N9741: FOLFOX vs FOLFIRI vs IFL in First-Line mCRC
Led N9741, the pivotal three-arm phase III trial demonstrating superiority of FOLFOX4 over IFL in first-line mCRC for overall survival, progression-free survival, and response rate, and showing the safety advantage of FOLFOX over irinotecan-based IFL. This trial was instrumental in the FDA approval of oxaliplatin for mCRC and established FOLFOX as a global standard.
Adjuvant Chemotherapy in Colon Cancer
Contributed leadership and data to multiple NCCTG trials establishing fluoropyrimidine-based and oxaliplatin-based adjuvant therapy standards in stage II and III colon cancer, including confirmation of the survival benefit of adjuvant FOLFOX in stage III disease.
NCCTG/Alliance Cooperative Group Leadership in GI Oncology
Served in key leadership roles within the NCCTG and Alliance for Clinical Trials in Oncology, overseeing a portfolio of GI oncology trials that have shaped treatment guidelines for colorectal, gastric, esophageal, and pancreatic cancers.
Chemotherapy Sequencing and Optimization in mCRC
Contributed analyses of sequential therapy strategies in mCRC, including the equivalence of FOLFOX and FOLFIRI as first-line options depending on the intended second-line sequence, influencing treatment planning and patient counseling in clinical practice.
Representative Works 代表性著作
Randomized Phase III Trial of FOLFOX4 Versus FOLFIRI Versus IFL in Advanced Colorectal Cancer (N9741)
Journal of Clinical Oncology (2004)
Landmark three-arm phase III trial demonstrating FOLFOX4 superiority over IFL in overall survival and response rate in first-line mCRC, providing the pivotal evidence base for FDA approval of oxaliplatin and establishing FOLFOX as the preferred first-line chemotherapy backbone.
Fluorouracil-Based Adjuvant Chemotherapy: State of the Art and Future Directions
Journal of Clinical Oncology (2001)
Comprehensive review summarizing the evidence base for fluoropyrimidine-based adjuvant therapy in colon cancer and outlining the rationale for adding oxaliplatin to adjuvant regimens, which was subsequently validated in the MOSAIC trial.
Updated Efficacy and Toxicity Analysis of Irinotecan and Oxaliplatin (IROX): Intergroup Trial N9741 in First-Line Treatment of Metastatic Colorectal Cancer
Cancer (2006)
Updated long-term follow-up of N9741 providing mature overall survival data and confirming FOLFOX4 as the superior first-line regimen, with detailed toxicity profiles informing clinical management.
Infusional Versus Bolus Fluorouracil in Combination with Oxaliplatin: NCCTG Adjuvant Colon Cancer Data
Journal of the National Cancer Institute (2007)
Cooperative group analysis evaluating fluorouracil delivery schedule in adjuvant oxaliplatin-based regimens for colon cancer, informing practical chemotherapy administration choices.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-05 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Richard M. Goldberg 的研究动态
Follow Richard M. Goldberg's research updates
留下邮箱，当我们发布与 Richard M. Goldberg（The Ohio State University Comprehensive Cancer Center – James Cancer Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment